Literature DB >> 15192042

Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels.

Rossana Mineo1, Angela Costantino, Franco Frasca, Laura Sciacca, Simona Russo, Riccardo Vigneri, Antonino Belfiore.   

Abstract

Met, the receptor for hepatocyte growth factor (HGF), is overexpressed in approximately 90% papillary thyroid carcinomas. To investigate the role of the HGF-Met system in these tumors, we examined HGF and Met expression in a variety of primary cultures, normal or malignant thyroid cells, and tissue specimens and analyzed the different HGF effects (promotion of mitogenesis, branching morphogenesis, and cell motility and invasion). In cancer specimens, HGF was produced at high levels by tumor stromal cells, and Met was constitutively phosphorylated in malignant cells. No HGF production was found in a panel of malignant thyroid cancer cells. Biological effects of HGF were examined in papillary cancer cell cultures with either high or low Met expression. High-Met cells were more sensitive to the growth effect of HGF (ED50 = 3-5 ng/ml and 10-15 ng/ml in high- or low-Met cells, respectively). Moreover, only high-Met cells underwent branching morphogenesis in response to HGF. In contrast, high-Met cells showed a reduced migration. Met down-regulation by small interfering RNAs resulted in enhanced cell migration and abrogation of branching morphogenesis in response to HGF. Conversely, Met overexpression impaired cell migration while favoring branching morphogenesis and cell adherence to substrate. These data suggest that both Met and HGF are overexpressed in papillary thyroid carcinomas, that Met is frequently activated in these carcinomas and may favor tumor growth, and that the abundance of Met expression may differently regulate cell growth, morphogenesis, and migration in response to HGF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15192042     DOI: 10.1210/en.2003-1762

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  17 in total

Review 1.  The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid.

Authors:  Sylvia L Asa
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Off-target effects of c-MET inhibitors on thyroid cancer cells.

Authors:  Yan Zhou; Conghui Zhao; Sigal Gery; Glenn D Braunstein; Ryoko Okamoto; Rocio Alvarez; Steven A Miles; Ngan B Doan; Jonathan W Said; Jiang Gu; H Phillip Koeffler
Journal:  Mol Cancer Ther       Date:  2013-10-29       Impact factor: 6.261

3.  c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death.

Authors:  Rong Bu; Shahab Uddin; Maqbool Ahmed; Azhar R Hussain; Saif Alsobhi; Tarek Amin; Abdurahman Al-Nuaim; Fouad Al-Dayel; Jehad Abubaker; Prashant Bavi; Khawla S Al-Kuraya
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

4.  Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases.

Authors:  Faina Linkov; Robert L Ferris; Zoya Yurkovetsky; Adele Marrangoni; Lyudmila Velikokhatnaya; William Gooding; Brian Nolan; Matthew Winans; Eric R Siegel; Anna Lokshin; Brendan C Stack
Journal:  Proteomics Clin Appl       Date:  2008-10-10       Impact factor: 3.494

5.  A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.

Authors:  Maria E Cabanillas; Marcia S Brose; Jaymes Holland; Kimberly C Ferguson; Steven I Sherman
Journal:  Thyroid       Date:  2014-08-27       Impact factor: 6.568

6.  Valproic acid, targets papillary thyroid cancer through inhibition of c-Met signalling pathway.

Authors:  Yan-Tao Fu; Hai-Bo Zheng; Le Zhou; Da-Qi Zhang; Xiao-Li Liu; Hui Sun
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

7.  Serum hepatocyte growth factor is increased in Hashimoto's thyroiditis whether or not it is associated with nodular goiter as compared with healthy non-goitrous individuals.

Authors:  R M Ruggeri; S Sciacchitano; A Vitale; P Cardelli; M Galletti; E Vitarelli; G Barresi; S Benvenga; F Trimarchi; M Trovato
Journal:  J Endocrinol Invest       Date:  2009-03-25       Impact factor: 4.256

Review 8.  The pituitary tumor transforming gene in thyroid cancer.

Authors:  G D Lewy; N Sharma; R I Seed; V E Smith; K Boelaert; C J McCabe
Journal:  J Endocrinol Invest       Date:  2012-04-05       Impact factor: 4.256

9.  Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.

Authors:  Naifa Lamki Busaidy; Maria E Cabanillas
Journal:  J Thyroid Res       Date:  2012-02-28

Review 10.  Cancer therapy using tumor-associated antigens to reduce side effects.

Authors:  David Siu
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 5.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.